ETV (KDM5B inhibitor) significantly improves the hepatic histopathology and reduces CHB progression, decreasing the likelihood of hepatocellular carcinoma development and increasing the survival rate of patients with hepatitis-virus-related liver tumors [5,21,23,28,33,34,35]. This evidence concerns the gene KDM5B and hepatocellular carcinoma.